Regeneron/Sanofi’s PSCK9 Inhibitor Might Need Two-Week Dosing Schedule
This article was originally published in The Pink Sheet Daily
Executive Summary
Fully human antibody for hypercholesterolemia is set to enter Phase III next month, and while the firms aren’t discussing the protocol, recent data suggest that REGN727/SRA236553 may need dosing every two weeks, rather than the more convenient monthly schedule.